Compounds > rogletimide
Page last updated: 2024-12-06

rogletimide

Cross-References

ID SourceID
PubMed CID56487
CHEMBL ID289116
SCHEMBL ID4281
MeSH IDM0142608

Synonyms (42)

Synonym
nsc619778
nsc-619778
pyridoglutethimide
NCI60_005808
rogletimide
121840-95-7
D05746
rogletimide (usan/inn)
2,6-piperidinedione, 3-ethyl-3-(4-pyridinyl)-
(+-)-pyridoglutethimide
racemic-pyridoglutethimide
2-ethyl-2-(4-pyridyl)glutarimide
3-pyg
3-ethyl-3-(4-pyridyl)piperidine-2,6-dione
92788-10-8
CHEMBL289116 ,
3-ethyl-4,5-dihydro-3h-[3,4'']bipyridinyl-2,6-dione
3-ethyl-3-pyridin-4-ylpiperidine-2,6-dione
bdbm50015985
rogletimide [usan:inn:ban]
14p4qr28qf ,
unii-14p4qr28qf
3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione
AM20050714
AKOS015904738
2,6-piperidinedione, 3-ethyl-3-(4-pyridinyl)-, (+/-)-
rogletimide [who-dd]
rogletimide [mart.]
rogletimide [usan]
(+/-)-2-ethyl-2-(4-pyridyl)glutarimide
rogletimide [inn]
(+/-)-pyridoglutethimide
SCHEMBL4281
(+/-) 3-ethyl-3-(4-pyridinyl)-2,6-piperidinedione
3-ethyl-3-(pyridin-4-yl)piperidine-2,6-dione
FT-0749860
QXKJWHWUDVQATH-UHFFFAOYSA-N
3-ethyl-3-(4-pyridyl)-2,6-piperidinedione
3-aminomethyl-biphenyl-4-ylamine
Q7359418
pyridoglutethimide; racemic pyridoglutethimide
DTXSID60869670

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" This report gives the results of a detailed pharmacokinetic and endocrine study of PyG in ten patients."( Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
Coombes, RC; Dowsett, M; Haynes, B; Jarman, M; Jones, A; Lonning, P; MacNeill, F; Mehta, A; Newton, C; Powles, TJ, 1991)		0.28
" This study investigates the pharmacokinetics of pyridoglutethimide in the rat and the rabbit: the plasma half-life is 6 hr in the rat and 16."( Pyridoglutethimide [3-ethyl-3-(4-pyridyl)-piperidine-2,6-dione], an analogue of aminoglutethimide. Metabolism and pharmacokinetics.
Goss, PE; Griggs, LJ; Jarman, M; Seago, A, 1986)		0.27

Dosage Studied

ExcerptRelevanceReference
" On subsequent repeated dosing with PyG, both the Km (4."( Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.
Coombes, RC; Dowsett, M; Griggs, LJ; Haynes, BP; Jarman, M; Jones, A; Lønning, PE; Mehta, A; Powles, T; Stein, R, 1991)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AromataseHomo sapiens (human)IC50 (µMol)20.00000.00001.290410.0000AID53546; AID53574; AID53575
AromataseHomo sapiens (human)Ki5.40000.00000.60469.5010AID53888; AID53889; AID54049
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AromataseHomo sapiens (human)Ka app0.28000.13000.20500.2800AID54046
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID53546Inhibition of Cytochrome P450 19A1 in human placenta1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Crystallographic and molecular modeling studies on 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione and its butyl analogue, inhibitors of mammalian aromatase. Comparison with natural substrates: prediction of enantioselectivity for N-alkyl derivatives.
AID53574Inhibitory activity against human placental cytochrome P450 19A11987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents.
AID53727Inhibition of Cytochrome P450 19A1 at 20 ug/mL1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Analogues of aminoglutethimide: selective inhibition of aromatase.
AID56619Inhibition of bovine adrenal desmolase at 50 ug/mL; None1985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Analogues of aminoglutethimide: selective inhibition of aromatase.
AID53889Inhibition of human placental cytochrome P450 19A1 with androstenedione1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents.
AID53888Inhibition of human placental cytochrome P450 19A1 with testosterone1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents.
AID23487Partition coefficient (logP)1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents.
AID54046Apparent inhibitory constant (Ka) for Cytochrome P450 19A11985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Analogues of aminoglutethimide: selective inhibition of aromatase.
AID53575Inhibition of human placental cytochrome P450 19A1 with androstenedione1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents.
AID54049Inhibitory constant (Ki) for Cytochrome P450 19A11985Journal of medicinal chemistry, Feb, Volume: 28, Issue:2
Analogues of aminoglutethimide: selective inhibition of aromatase.
AID229813Ratio of androstenedione-Ki to testosterone-Ki for human placental cytochrome P450 19A11987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substituents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (15.79)18.7374
1990's15 (78.95)18.2507
2000's1 (5.26)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.33 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.76%)5.53%
Reviews4 (19.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (76.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aminoglutethimide
Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.		7.86191dicarboximide;
piperidones;
substituted aniline		adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
anastrozole
[no description available]		4.0120nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
glutethimide
Glutethimide: A hypnotic and sedative. Its use has been largely superseded by other drugs.		1.9810piperidines
letrozole
[no description available]		4.0120nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
estrone
Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.		3.492017-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols		antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite
androstenedione
Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.		5.436017-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
formestane
[no description available]		5.14017-oxo steroid;
3-oxo-Delta(4) steroid;
enol;
hydroxy steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
fadrozole
Fadrozole: A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer.		4.2830imidazopyridine
aromasil
[no description available]		3.11017-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		4.01201,2,3-triazole
cyclohexylaminoglutethimide
cyclohexylaminoglutethimide: structure given in first source		1.9810
tamoxifen
[no description available]		3.0910stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
estrone sulfate
estrone sulfate: sulfoconjugated estrone; RN given refers to parent cpd		1.971017-oxo steroid;
steroid sulfate		human metabolite;
mouse metabolite
vorozole
vorozole: structure given in first source; vorozole/R 83842 is ((+)/dextro-isomer), RN 129731-10-8; R 83839 ((-)/levo-isomer)		4.0120benzotriazoles
cellulose
DEAE-Cellulose: Cellulose derivative used in chromatography, as ion-exchange material, and for various industrial applications.		2.0110glycoside
ConditionIndicatedRelationship StrengthStudiesTrials
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0110
Breast Cancer
[description not available]		011.8181
Hormone-Dependent Neoplasms
[description not available]		02.9110
Breast Neoplasms
Tumors or cancer of the human BREAST.		06.8181
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9710
Menopause
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.		04.6821
chemdatabank.com